New analysis being introduced at this 12 months’s European Congress on Obesity (ECO 2025) has discovered that sufferers of a web based obesity clinic achieved comparable weight loss to that reported in clinical trials – however with lower than half the treatment. The research is to be printed within the journal The Lancet Digital Health.
Patients who adopted the programme had a mean weight loss of 16.7% (16.8kg/2st 9lb) after 64 weeks, which is on par with that seen in randomised managed trials of the identical drug, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Achieving the identical weight loss in day-to-day life as within the tightly managed circumstances of a clinical trial, whereas additionally utilizing lower doses of medicine, has many potential advantages, from lower prices and fewer side-effects for sufferers, to making sure that shares of the drug go additional.”
Dr. Henrik Gudbergsen, lead researcher and Chief Medical Officer of Embla, a web based weight loss service
Semaglutide and different GLP-1 agonists for weight loss have had spectacular leads to clinical trials. However, real-world trials have reported smaller weight losses and lack particulars about whether or not sufferers are additionally making life-style modifications that may improve the probability of their attaining optimum weight loss.
Real-world trial outcomes additionally recommend that few sufferers comply with the usual dosing schedule, with most staying on lower doses.
In the primary research of its type, Dr Gudbergsen and colleagues on the University of Copenhagen evaluated the real-world results of a web based weight loss programme that gives intensive behavioural remedy and recommendation on weight-reduction plan and train, in addition to doses of semaglutide which might be tailor-made to particular person sufferers.
The cohort research concerned 2,694 people in Denmark (78% feminine, common age 47 years, common BMI 34.3, common physique weight 100.5kg/15st 12lb) who have been enrolled in a weight administration programme run by way of the Embla app, accessible in Denmark and within the UK.
The programme included recommendation on healthy to eat, rising train and on how you can use cognitive behavioural remedy (CBT) and different therapies to beat the psychological boundaries to weight loss, entry to docs, nurses and psychologists by way of the AI-powered app and a course of the weight- loss drug semaglutide (Wegovy).
The customary dosing schedule, by which a low preliminary dose of 0.25 mg as soon as weekly is elevated each 4 weeks for 16 weeks to a most dose of two.4mg (which the affected person stays on till remedy ends), was tailor-made to particular person sufferers.
Patients obtained the bottom efficient dose, and will increase have been solely thought of if they’d stopped making progress. If they maintained a weekly weight discount >0.5% of their physique weight and skilled manageable ranges of side-effects and starvation, they remained on the present dose. Treatment continued on this method till they reached their desired weight or a BMI of 25 – an strategy generally known as “deal with to focus on”.
After 26, 64 and 76 weeks, 1,580, 712 and 465 sufferers, respectively, have been nonetheless participating within the programme.
Average weight loss amongst those that have been nonetheless participating within the programme was 12.2% (12.2kg/1st 13lb) at week 26, 16.2% (16.3kg/2st 8lb) at week 52 and 16.7% (16.8kg, 2st 9lb) at week 64.
The researchers observe that that is much like the 15-16% weight loss at 64 weeks achieved by sufferers who took half in clinical trials by which semaglutide was mixed with life-style interventions reminiscent of calorie-controlled diets and behavioural remedy.1-3
However, it was achieved with lower than half the treatment used within the clinical trials. The common dose of semaglutide on this research was about 1mg/week and solely 28.8% of sufferers reached doses increased than this.
In distinction, about 90% of the sufferers within the clinical trials reached doses of two.4mg/week.
Dr Gubdergsen, who can also be an affiliate professor on the University of Copenhagen, says: “By combining weight-reduction plan and train recommendation with psychological teaching and personalising sufferers’ doses of semaglutide it was potential to realize the identical quantity of weight loss with lower doses of the drug.”
Some 98% of the 515 sufferers with a reported weight at weeks 52-64 achieved a minimum of 5% weight loss and 82%, 51%, and 23% achieved 10%, 15% and 20% weight loss, respectively.
Females had a better weight loss than males (17·6% vs 13·4 %) and sufferers who used the net app extra misplaced extra weight than those that used it much less.
The evaluation additionally discovered that sufferers’ weight loss was comparable, no matter their preliminary BMI, age or the quantity of semaglutide used. In different phrases, lower doses of semaglutide have been simply as efficient as increased ones.
Side-effects, reminiscent of nausea, vomiting, and abdomen ache have been usually gentle and transient.
The research’s limitations embody using self-reported knowledge and the shortage of a management group.
Dr Gudbergsen concludes: “Our outcomes present that by giving personalised doses of semaglutide alongside with weight-reduction plan, train and psychological assist, it’s potential for sufferers to realize clinical trial-level weight loss of their day-to-day lives.
“Our ‘treat-to-target’ strategy, by which quantity of treatment was tailor-made to every affected person’s objectives, allowed us to maintain doses as little as potential, which ought to imply lower prices and fewer side-effects for sufferers.
“This strategy was efficient throughout all age teams and all beginning weights and in each sexes.”